European Primary Care Cardiovascular Society

COVID-19

Highly-purified icosapent ethyl does not reduce clinical outcomes in non-hospitalized COVID-19 patients

News - Nov. 15, 2021

AHA 2021 The PREPARE IT-2 trial enrolled non-hospitalized COVID-19 patients and showed that icosapent ethyl did not reduce COVID-19-related hospitalization or death compared to placebo after 28 days.

No improvement of outcomes with therapeutic-dose of heparin in critically ill COVID-19 patients

Literature - Aug. 16, 2021 - The REMAP-CAP, ACTIV-4a, and ATTACC Investigators, et al. - NEJM 2021
In an open-label, multiplatform, randomized trial, therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin did not improve clinical outcomes compared to usual-care pharmacologic thromboprophylaxis in critically ill COVID-19 patients.

In an open-label, multiplatform, randomized trial, therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin did not improve clinical outcomes compared to usual-care pharmacologic thromboprophylaxis in critically ill COVID-19 patients.

COVID-19 vaccine-induced atypical thrombosis and thrombocytopenia in some individuals

Literature - Apr. 26, 2021 - Scully M, et al. - N Engl J Med. 2021 Apr 16.

This study described the clinical features of 23 patients who after receiving the first dose of ChAdOx1 nCoV-19 vaccine developed atypical platelet factor 4 (PF4)-dependent thrombosis and/or thrombocytopenia that resembles heparin-induced thrombocytopenia.

Some cases after COVID-19 vaccination show clinical resemblance of heparin-induced thrombocytopenia

Literature - Apr. 6, 2021 - Greinacher A et al. - Research Square 2021 (NOT PEER-REVIEWED)

Some cases of thrombotic events combined with thrombocytopenia have been described after COVID-19 vaccination with AZD1222. This thrombotic disorder clinically resembles heparin-induced thrombocytopenia, with a different serological profile.

High incidence of thrombotic complications in first and second COVID-19 wave

5' education - Mar. 5, 2021 - Fleur Kaptein, MD
Incidence of thrombotic complications remained high in hospitalized COVID-19 patients in the second wave. Thromboprophylaxis is therefore warranted in these patients.

Incidence of thrombotic complications remained high in hospitalized COVID-19 patients in the second wave. Thromboprophylaxis is therefore warranted in these patients.

Incidence of thrombotic complications in hospitalized COVID-19 patients remained high in second wave

Literature - Mar. 5, 2021 - Kaptein FHJ et al., - Thrombosis Research 2020.

Risk of overall mortality in COVID-19 patients was lower in the second wave, compared with the first wave. However, cumulative incidences of thrombotic complications remained high in the second wave.

During COVID-19 pandemic, lower rate of cholesterol testing

Literature - Mar. 5, 2021 - Gumuser ED, et al. - Am J Prev Cardiol 2021
Compared to the same period in 2019, cholesterol testing rate was almost 40% lower between March-September 2020 when analyzing data from a healthcare system in New England, USA.

Compared to the same period in 2019, cholesterol testing rate was almost 40% lower between March-September 2020 when analyzing data from a healthcare system in New England, USA.

High risk for poor outcomes in patients with HF hospitalized for COVID-19

Literature - Jan. 22, 2021 - Alvarez-Garcia J, et al. - J Am Coll Cardiol. 2020

Patients with HF admitted to hospital for COVID-19 had increased risk for in-hospital mortality and needed more often ICU care and intubation and mechanical ventilation compared to patients without HF.

Dysfunction of the endothelium in COVID-19

Literature - Jan. 21, 2021 - Evans PC et al., - Cardiovasc Res. 2020

This position paper discusses the cause and consequences of endothelial injury and dysfunction in COVID-19.

COVID-19 patients with myocardial injury and echocardiographic abnormalities have Increased in-hospital mortality

Literature - Dec. 10, 2020 - Giustino G, et al. - J Am Coll Cardiol. 2020

A study of 305 hospitalized COVID-19 patients showed that approximately two-third of patients with evidence of myocardial injuries had echocardiographic abnormalities. In these patients, risk of in-hospital mortality was increased.

COVID-19 and HFpEF

News - Dec. 10, 2020
This viewpoint article in JAMA reviews the latest findings on the risk of heart failure, particularly HFpEF, in those who developed acute COVID-19 and those who have recovered from the illness.

This viewpoint article in JAMA reviews the latest findings on the risk of heart failure, particularly HFpEF, in those who developed acute COVID-19 and those who have recovered from the illness.

An update on COVID-19 at the AHA Scientific Sessions

10' education - Dec. 3, 2020 - Anthony Fauci, MD
Anthony Fauci gives a presentation on COVID-19: Public health and scientific challenges.

AHA 2020 Anthony Fauci gives a presentation on COVID-19: Public health and scientific challenges.

COVID-19